The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 25, 2015

Filed:

Sep. 02, 2014
Applicant:

Asana Biosciences, Llc, Bridgewater, NJ (US);

Inventors:

Roger Astbury Smith, Chester Springs, PA (US);

Scott Kevin Thompson, Phoenixville, PA (US);

Subramanya Hosahalli, Bangalore, IN;

Mallesham Bejugam, Parbhani, IN;

Srinivas Nanduri, Hyderabad, IN;

Sunil Kumar Panigrahi, Kantamal, IN;

Natarajan Mahalingam, Ariyalur, IN;

Assignee:

Asana Biosciences, LLC, Bridgewater, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/535 (2006.01); C07D 413/14 (2006.01); C07D 413/04 (2006.01); C07D 239/72 (2006.01); C07D 239/42 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 405/04 (2006.01); C07D 405/14 (2006.01); C07D 471/04 (2006.01); C07D 295/155 (2006.01); C07D 409/04 (2006.01);
U.S. Cl.
CPC ...
C07D 239/72 (2013.01); A61K 31/535 (2013.01); C07D 239/42 (2013.01); C07D 295/155 (2013.01); C07D 401/04 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 405/04 (2013.01); C07D 405/14 (2013.01); C07D 409/04 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01);
Abstract

The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.


Find Patent Forward Citations

Loading…